| Literature DB >> 35744667 |
Ingrid Nayara Marcelino Santos1, Mariana Neri Lucas Kurihara1, Fernanda Fernandes Santos2, Tiago Barcelos Valiatti2, Juliana Thalita Paulino da Silva2, Antônio Carlos Campos Pignatari1, Mauro José Salles1,3,4.
Abstract
Staphylococcus spp. remain the leading biofilm-forming agents causing orthopedic implant-associated infections (OIAI). This is a descriptive study of phenotypic and genomic features identified in clinical isolates of S. aureus and coagulase-negative Staphylococcus (CoNS) recovered from OIAIs patients that progressed to treatment failure. Ten isolates were identified by matrix-time-of-flight laser-assisted desorption mass spectrometry (MALDI-TOF-MS) and tested for antibiotic susceptibility and biofilm formation. Genotypic characteristics, including, MLST (Multi Locus Sequence Typing), SCCmec typing, virulence and resistance genes were assessed by whole-genome sequencing (WGS). All S. aureus harbored mecA, blaZ, and multiple resistance genes for aminoglycosides and quinolones. All MRSA were strong biofilm producers harboring the complete icaADBC and icaR operon. Seven CoNS isolates comprising five species (S. epidermidis, S. haemolyticus, S. sciuri, S. capitis and S. lugdunensis) were analyzed, with mecA gene detected in five isolates. S. haemolitycus (isolate 95), and S. lugdunensis were unable to form biofilm and did not harbor the complete icaADBCR operon. High variability of adhesion genes was detected, with atl, ebp, icaADBC operon, and IS256 being the most common. In conclusion, MRSA and CoNS isolates carrying genes for biofilm production, and resistance to β-lactam and aminoglycosides are associated with treatment failure in OIAIs.Entities:
Keywords: Staphylococcus aureus; bacterial resistance; biofilm; coagulase-negative Staphylococci; orthopedic infections; sonication; whole-genome sequencing
Year: 2022 PMID: 35744667 PMCID: PMC9230661 DOI: 10.3390/microorganisms10061149
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Clinical data of patients with infections associated with orthopedic implants.
| Patient | Age | Gender | Comorbidities | Preoperative Diagnosis | Source | Implant | Bacterial Identification (MALDI-TOF MS) | Empirical Antibiotic Therapy |
|---|---|---|---|---|---|---|---|---|
| 215 | 38 | M | DM | Chronic spinal disease | Spine | Plate/screw |
| Ciprofloxacin |
| 260 | 89 | M | DM and Tumor | Closed fracture | tibia/fibula | Plate/screw |
| Ciprofloxacin |
| 371 | 43 | M | Closed fracture | ankle | Plate/screw |
| Ciprofloxacin | |
| 216 | 47 | M | DM and Tumor | Closed fracture | hip | Plate/screw |
| Cefazolin |
| 403 | 67 | M | _ | Osteoarthrosis | hip | Arthroplasty |
| Vancomycin |
| 53 | 66 | M | _ | Osteoarthrosis | hip | Arthroplasty |
| Vancomycin |
| 95 | 67 | F | DM and Coronariopathy | Osteoarthrosis | knee | Arthroplasty |
| Vancomycin |
| 160 | 53 | F | RA | Osteoarthrosis | hip | Arthroplasty |
| Vancomycin |
| 226 | 44 | F | _ | Tumor lesion | hip | Arthroplasty |
| Vancomycin |
| 167 | 79 | F | Tumor | Open fracture | ankle | Fixing pin |
| Cefazolin + Gentamicin |
F: female gender; M: male gender; DM: diabetes melitus; RA: rheumatoid arthritis; MALDI-TOF MS: Matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy.
Molecular epidemiology of Staphylococcus spp. clinical isolates included in the study.
| Isolate ID | Species | Molecular Characterization | |||
|---|---|---|---|---|---|
|
|
|
|
| ||
| 215 |
| I (1B) | 5 | CC5 | JAHMMM000000000 |
| 260 |
| V (5C2) | 5 | CC5 | JAHMMN000000000 |
| 371 |
| (2A) | 105 | CC5 | JAHMMO000000000 |
| 216 |
| III (3A) | 2 | CC2 | JAHMMP000000000 |
| 403 |
| _ | 183 | _ | JAHMMQ000000000 |
| 53 |
| _ | 9 | _ | JAHMMR000000000 |
| 95 |
| _ | 3 | _ | JAHMMS000000000 |
| 160 |
| _ | _ | _ | JAHMMT000000000 |
| 226 |
| III (3A) | _ | _ | JAHMMU000000000 |
| 167 |
| _ | 2 | CC2 | JAHMMV000000000 |
CC Clonal Complex; SCCmec Staphylococcal Cassette Chromosome mec; ST Sequence Type.
Phenotypic resistance profile using disk diffusion test, and broth microdilution and E-test for minimal inhibitory concentration (MIC) characterization of Staphylococcus spp. isolates included in the study.
| ID | Species | MIC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Broth Microdilution | E-Test | ||||||||||
| (µg/mL) | |||||||||||
| VAN | OXA | CLI | ERY | LEV | LNZ | GEN | TGC | TET | RIF | ||
| 215 |
| 1.0 | >2.0 | 2.0 | <0.5 | 1.0 | 2.0 | 2.0 | 0.25 | 0.75 | <0.016 |
| 260 |
| 0.5 | >2.0 | 0.25 | <0.5 | 1.0 | 2.0 | 2.0 | 0.25 | 0.19 | <0.016 |
| 371 |
| 0.5 | >2.0 | 1.0 | <0.5 | 1.0 | 2.0 | <1.0 | 0.25 | 0.5 | <0.016 |
| 216 |
| 4.0 | >2.0 | 1 | <0.5 | >4.0 | 2.0 | 2.0 | 0.25 | 0.094 | >256 |
| 403 |
| 1.0 | <0.25 | <0.25 | <0.5 | <0.5 | 2.0 | >8.0 | 0.25 | 0.125 | 0. 016 |
| 53 |
| 0.5 | >2.0 | <0.25 | <0.5 | <0.5 | 2.0 | 2.0 | 2.0 | 24 | <0.016 |
| 95 |
| 1.0 | >2.0 | >2.0 | <0.5 | >4.0 | 1.0 | >8.0 | 1.0 | 32 | <0.016 |
| 160 |
| 2.0 | >2.0 | >2.0 | >4.0 | >4.0 | 1.0 | >8.0 | 1.0 | 0.75 | <0.016 |
| 226 |
| 1.0 | >2.0 | 2.0 | <0.5 | 1.0 | 2.0 | <1.0 | 0.25 | 0.5 | <0.016 |
| 167 |
| 1.0 | 0.5 | <0.25 | <0.5 | <0.5 | 0.5 | <1.0 | 0.06 | 0.125 | <0.016 |
SA Sthapylococus aureus; SE Staphylococcus epidermidis; SH Staphylococcus haemolyticus; SC Staphylococcus capitis; SSc Staphylococcus sciuri; SL Staphylococus lugdunensis; FOX Cefoxitin; OXA Oxacillin; CLI Clindamycin; ERY Erithromycin; NOR Norfloxacin; GEN Gentamicin; TET Tetracycline; RIF Rifampicin; SXT trimethoprim sulfamethoxazole; MIC: minimal inhibitory concentration.
Genotypic resistance profile with respective genes of Staphylococcus spp. isolates included in the study.
| Antibiotics | Resistance Genes |
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 215 | 260 | 371 | 216 | 403 | 53 | 95 | 160 | 226 | 167 | ||
| β-lactam |
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
|
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| Aminoglycosides |
| ✓ | ✓ | ||||||||
|
| ✓ | ✓ | ✓ | ||||||||
|
| ✓ | ✓ | ✓ | ✓ | |||||||
|
| ✓ | ✓ | ✓ | ||||||||
|
| ✓ | ✓ | |||||||||
|
| ✓ | ||||||||||
| MLSb |
| ✓ | ✓ | ||||||||
|
| ✓ | ||||||||||
|
| ✓ | ✓ | |||||||||
| Tetraciclyn |
| ✓ | ✓ | ||||||||
|
| ✓ | ✓ | |||||||||
| Quinolones |
| ✓ | ✓ | ||||||||
|
| ✓ | ✓ | |||||||||
|
| ✓ | ✓ | |||||||||
|
| ✓ | ||||||||||
|
| ✓ | ||||||||||
|
| ✓ | ✓ | |||||||||
|
| ✓ | ✓ | ✓ | ||||||||
|
| ✓ | ✓ | ✓ | ||||||||
| Others |
| ✓ | ✓ | ✓ | |||||||
|
| ✓ | ✓ | ✓ | ||||||||
|
| ✓ | ||||||||||
|
| ✓ | ✓ | ✓ | ||||||||
|
| ✓ | ||||||||||
|
| ✓ | ||||||||||
MLSb resistance to macrolides, lincosamides and group B streptogramins. SA Sthapylococus aureus; SE Staphylococcus epidermidis; SH Staphylococcus haemolyticus; SC Staphylococcus capitis; SSc Staphylococcus sciuri; SL Staphylococus lugdunensis.
Evaluation of phenotypic biofilm formation and detection of biofilm forming genes and adhesins (MSCRAMMs) of clinical isolates.
| Species ID | Biofilm Formation | PIA | Autolysin | FBP | EBP | FP | AF | ECAP/MHCAP | Sdr-FP |
|---|---|---|---|---|---|---|---|---|---|
|
| Strong |
|
|
|
|
|
|
| |
| 215 | |||||||||
|
| Strong |
|
|
|
|
|
|
|
|
| 260 | |||||||||
|
| Strong |
|
|
|
|
|
|
|
|
| 371 | |||||||||
|
| Strong |
|
|
|
|
|
| ||
| 216 | |||||||||
|
| Strong |
|
|
|
| ||||
| 403 | |||||||||
|
| Strong |
|
| ||||||
| 53 | |||||||||
|
| non- |
|
|
| |||||
| 95 | adherent | ||||||||
|
| weak |
|
|
|
| ||||
| 160 | |||||||||
|
| Strong | ||||||||
| 226 | |||||||||
|
| non- |
| |||||||
| 167 | adherent |
PIA: Polyssacharide intercellular adhesin; FBP: fibronectin binding proteins; EBP: elastin binding proteins; FB: fibrinectin protein; AF: Agglutination factor; Sdr-FP: Sdr family proteins; ECA/MHC AP: Extracellular adhesion protein/MHC analog protein; MSCRAMMs Microbial Surface Components Recognizing Adhesive Matrix Molecules.